Rubedo Life Sciences

Focus: Rubedo Life Sciences is a biotech company focused on senescence-targeting drug discovery for age-related diseases, currently advancing early-stage candidates in dermatology. Founded in 1999 and publicly listed, the company operates a lean R&D platform in Sunnyvale, CA.

Unknown

Profile data last refreshed 7h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Rubedo Life Sciences

AI assessmentNot Hiring

No open roles listed right now. Follow Rubedo Life Sciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RLS-1496 1.0% cream

Actinic Keratosis (AK)

PHASE_1_2

Clinical Trials (1)

NCT07340697Evaluate RLS-1496 Topical Cream for Actinic Keratosis

Phase 1/2

Help build intelligence for Rubedo Life Sciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering senotherapy platform addresses a novel mechanism in aging biology with demonstrated early efficacy signals in RLS-1496 for actinic keratosis.
Public company status provides equity upside and career stability compared to pre-revenue biotech, with active clinical development underway.
Tight, focused pipeline allows individual contributors to see clear impact on company direction and scientific validation.

Watch Out For

Only one early-stage program (Phase 1/2) limits near-term value inflection and clinical learning velocity; no Phase 3 programs in sight.
Zero active job openings reported; hiring appears stalled or highly selective, making this difficult entry point despite public status.
Limited public financial transparency and minimal disclosure around cash runway, runway, or revenue generation create uncertainty around long-term viability.

Generated by Claude from Rubedo Life Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.